Compile Data Set for Download or QSAR
Report error Found 297 Enz. Inhib. hit(s) with all data for entry = 8926
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383718(US10280150, Cmpd No I-1 | US10550099, Compound I-1)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383719(US10280150, Cmpd No I-2 | US10550099, Compound I-2)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383719(US10280150, Cmpd No I-2 | US10550099, Compound I-2)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383721(US10280150, Cmpd No I-4 | US10550099, Compound I-4)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383721(US10280150, Cmpd No I-4 | US10550099, Compound I-4)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383722(US10280150, Cmpd No I-5 | US10550099, Compound I-5)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383725(US10280150, Cmpd No I-8 | US10550099, Compound I-8)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383725(US10280150, Cmpd No I-8 | US10550099, Compound I-8)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383727(US10280150, Cmpd No I-10 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383728(US10280150, Cmpd No I-11 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383728(US10280150, Cmpd No I-11 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383730(US10280150, Cmpd No I-13 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383739(US10280150, Cmpd No I-22 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383742(US10280150, Cmpd No I-25 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383742(US10280150, Cmpd No I-25 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383743(US10280150, Cmpd No I-26 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383746(US10280150, Cmpd No I-29 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383746(US10280150, Cmpd No I-29 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383749(US10280150, Cmpd No I-32 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383750(US10280150, Cmpd No I-33 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383750(US10280150, Cmpd No I-33 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383753(US10280150, Cmpd No I-36 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383756(US10280150, Cmpd No I-39 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383757(US10280150, Cmpd No I-40 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383759(US10280150, Cmpd No I-42 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383759(US10280150, Cmpd No I-42 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383761(US10280150, Cmpd No I-44 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383761(US10280150, Cmpd No I-44 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383763(US10280150, Cmpd No I-46 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383763(US10280150, Cmpd No I-46 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383765(US10280150, Cmpd No I-48 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383768(US10280150, Cmpd No I-51 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM429845(US10550099, Compound I-53)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383775(US10280150, Cmpd No I-58 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383776(US10280150, Cmpd No I-59 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383777(US10280150, Cmpd No I-60 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383778(US10280150, Cmpd No I-61 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383778(US10280150, Cmpd No I-61 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383780(US10280150, Cmpd No I-63 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383780(US10280150, Cmpd No I-63 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383781(US10280150, Cmpd No I-64 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383785(US10280150, Cmpd No I-68 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383785(US10280150, Cmpd No I-68 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383788(US10280150, Cmpd No I-71 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383792(US10280150, Cmpd No I-75 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383796(US10280150, Cmpd No I-79 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383797(US10280150, Cmpd No I-80 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383798(US10280150, Cmpd No I-81 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383805(US10280150, Cmpd No I-88 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Forma Therapeutics

US Patent
LigandPNGBDBM383813(US10280150, Cmpd No I-96 | US10550099, Compound I-...)
Affinity DataIC50: 100nMAssay Description:Assays were performed in a 384-well black plate. An aliquot of 250 nL of compound was incubated with 10 μL of 30 nM IDH1-R132H or 10 nM IDH1-R13...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2020
Entry Details
Go to US Patent

Displayed 1 to 50 (of 297 total ) | Next | Last >>
Jump to: